Navigation Links
Drug May Ease Cognitive Effects of Huntington's
Date:2/9/2010

Small study reports improvement in thinking skills,,

TUESDAY, Feb. 9 (HealthDay News) -- An experimental drug may improve thinking, learning and memory skills in people with Huntington's disease, an inherited neurodegenerative disorder, new research says.

Huntington's affects movement, behavior and cognitive abilities, and people with the disease usually die within 10 to 30 years of its onset. Cognitive problems begin early in the disease and increase as Huntington's progresses, leading to the inability to work or perform normal daily activities.

Currently, the only approved therapy for Huntington's is tetrabenazine, which treats movement problems but does not prevent cognitive decline or change the course of the disease.

In the new study, researchers assessed the safety and tolerability of a new drug with the proposed generic name latrepirdine, in people with mild to moderate Huntington's disease. The drug stabilizes and improves the function of mitochondria, parts of cells that help convert food into energy. Previous research has suggested that mitochondria abnormalities could play a role in Huntington's.

For 90 days, 46 people took 20 milligrams of latrepirdine three times a day, and 45 others took a placebo. The researchers said the drug was well-tolerated (87 percent of people taking latrepirdine completed the study, compared with 82 percent of the others), and the rates of adverse events were 70 percent in the treatment group, 80 percent in the placebo group.

The researchers also found that average scores on scales rating overall cognitive function improved in the treatment group and remained the same in the placebo group.

"Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well-tolerated for 90 days in patients with Huntington's disease and may have a beneficial effect on cognition," wrote Dr. Karl Kieburtz, of the School of Medicine and Dentistry at the University of Rochester in New York, and his colleagues.

"Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington's disease," they added.

The study is published in the February issue of Archives of Neurology.

More information

We Move has more about Huntington's disease.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, Feb. 8, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Hypertension may predict dementia in older adults with certain cognitive deficits
2. HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training.
3. New compound improves cognitive decline, symptoms of Alzheimers disease in rodents
4. First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains
5. Expert Panel Reaches Consensus on Our Ability to Improve Cognitive Health
6. Study finds significantly worse outcomes in cancer patients with cognitive impairment
7. Caffeine doesnt reverse the negative cognitive impact of alcohol, study shows
8. Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries
9. Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform
10. Diet, Cognitive Ability May Play Role in Heart Disease
11. HAPPYneuron Launches Beta Program for Innovative Cognitive Rehab Tools at AMIA Conference in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 02, 2016 , ... Metabolic Code (MC) and ... and help doctors more efficiently manage their practice. Power2Practice is adding MC’s ... for Integrative and Functional Medicine. , The Metabolic Code platform provides a ...
(Date:12/4/2016)... ... December 03, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... A Wine Tasting Event in New York City, with long-time partners The Paul ...
(Date:12/4/2016)... Viejo, California (PRWEB) , ... December 03, 2016 ... ... 2 lower thirds, 4 transitions and many more tools allowing FCPX editors to ... CEO of Pixel Film Studios. , Perfect Harmony contains a beautifully designed ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint Medicines ... discovering and developing targeted kinase medicines for patients ... its ongoing Phase 1 trial evaluating BLU-285, an ... advanced systemic mastocytosis (SM). Blueprint Medicines is developing ... D816V mutant KIT. Approximately 90 to 95 percent ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... NEW ORLEANS , Dec. 2, 2016  Former Attorney ... Foti, Jr., Esq. , a partner at the law firm ... has commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in ... an "antitrust investigation by the Justice Department, begun about two ...
Breaking Medicine Technology: